S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)

bluebird bio (BLUE) Stock Price, News & Analysis

$1.29
-0.08 (-5.49%)
(As of 02:10 PM ET)
Today's Range
$1.28
$1.42
50-Day Range
$0.91
$1.75
52-Week Range
$0.88
$5.53
Volume
4.22 million shs
Average Volume
9.85 million shs
Market Capitalization
$141.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.87

bluebird bio MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
338.1% Upside
$5.87 Price Target
Short Interest
Healthy
31.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of bluebird bio in the last 14 days
Based on 45 Articles This Week
Insider Trading
Selling Shares
$9,503 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.78) to ($1.98) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.45 out of 5 stars

Medical Sector

304th out of 939 stocks

Biological Products, Except Diagnostic Industry

42nd out of 154 stocks

BLUE stock logo

About bluebird bio Stock (NASDAQ:BLUE)

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

BLUE Stock Price History

BLUE Stock News Headlines

Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments (BLUE)
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
MarketBeat Week in Review – 2/26 - 3/1 (BLUE)
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
bluebird bio Stock Signals Potential to be a Multi-bagger (BLUE)
Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could do
bluebird bio Stock Signals Potential to be a Multi-bagger
It isn't often that you can find the right story at the right time to give you a good chance of multiplying your wealth; these so-called multi-bagger stocks get their name because their price sees a pop of more than 100%. Driven by a good story and other factors to help the jump happen.
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Q4 2023 bluebird bio Inc Earnings Call
bluebird bio (NASDAQ:BLUE) Trading Down 6.2%
bluebird bio Is Priced Below IP Value
See More Headlines
Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
3/28/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
323
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.87
High Stock Price Target
$13.00
Low Stock Price Target
$1.02
Potential Upside/Downside
+344.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

Net Income
$-266,580,000.00
Net Margins
-419.64%
Pretax Margin
-419.50%

Debt

Sales & Book Value

Annual Sales
$3.60 million
Book Value
$2.37 per share

Miscellaneous

Free Float
107,040,000
Market Cap
$144.33 million
Optionable
Optionable
Beta
0.75
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Andrew ObenshainMr. Andrew Obenshain (Age 50)
    President, CEO & Director
    Comp: $1.04M
  • Mr. Thomas J. Klima (Age 52)
    Chief Commercial Officer & COO
    Comp: $654.97k
  • Mr. Richard A. Colvin M.D. (Age 58)
    Ph.D., Chief Medical Officer
    Comp: $696.24k
  • Mr. Christopher Krawtschuk CPA (Age 50)
    CFO, Principal Accounting Officer & Treasurer
  • Mr. Joseph D. Vittiglio Esq. (Age 52)
    J.D., Chief Legal & Business Officer and Secretary
  • Jess Rowlands
    Head of Corporate Communications
  • Ms. Andrea Walton
    Chief People Officer
  • Mr. Kasra Kasraian
    Senior Vice President of Technical Development & Operations
  • Mr. Scott Shoemaker
    Senior Vice President of Quality
  • Ms. Sarah Alspach
    Senior Vice President of External Affairs

BLUE Stock Analysis - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings
or view top-rated stocks.

What is bluebird bio's stock price target for 2024?

12 brokerages have issued 1 year price targets for bluebird bio's stock. Their BLUE share price targets range from $1.02 to $13.00. On average, they predict the company's stock price to reach $5.87 in the next twelve months. This suggests a possible upside of 338.1% from the stock's current price.
View analysts price targets for BLUE
or view top-rated stocks among Wall Street analysts.

How have BLUE shares performed in 2024?

bluebird bio's stock was trading at $1.38 at the beginning of 2024. Since then, BLUE shares have decreased by 2.9% and is now trading at $1.34.
View the best growth stocks for 2024 here
.

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our BLUE earnings forecast
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) posted its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.03. The biotechnology company earned $12.40 million during the quarter, compared to the consensus estimate of $13.56 million. bluebird bio had a negative net margin of 419.64% and a negative trailing twelve-month return on equity of 34.32%. The company's revenue was up 17364.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.92) earnings per share.

What ETFs hold bluebird bio's stock?
What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.03%), Vanguard Group Inc. (8.03%), Granahan Investment Management LLC (7.39%), Norges Bank (3.65%), Palo Alto Investors LP (3.05%) and Ghisallo Capital Management LLC (2.88%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima.
View institutional ownership trends
.

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLUE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners